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AbstrACt 
Objective Direct-acting antivirals have opened an 
opportunity for controlling hepatitis C virus (HCV) infection 
in Pakistan, where 10% of the global infection burden 
is found. We aimed to evaluate the implications of five 
treatment programme scenarios for HCV treatment as 
prevention (HCV-TasP) in Pakistan.
Design An age-structured mathematical model was used 
to evaluate programme impact using epidemiological and 
programme indicators.
setting Total Pakistan population.
Participants Total Pakistan HCV-infected population.
Interventions HCV treatment programme scenarios from 
2018 up to 2030.
results By 2030 across the five HCV-TasP scenarios, 
0.6–7.3 million treatments were administered, treatment 
coverage reached between 3.7% and 98.7%, prevalence 
of chronic infection reached 2.4%–0.03%, incidence 
reduction ranged between 41% and 99%, program-
attributed reduction in incidence rate ranged between 
7.2% and 98.5% and number of averted infections 
ranged between 126 221 and 750 547. Annual incidence 
rate reduction in the first decade of the programme 
was around 6%–18%. Number of treatments needed to 
prevent one new infection ranged between 4.7–9.8, at 
a drug cost of about US$900. Cost of the programme by 
2030, in the most ambitious elimination scenario, reached 
US$708 million. Stipulated WHO target for 2030 cannot be 
accomplished without scaling up treatment to 490 000 per 
year, and maintaining it for a decade.
Conclusion HCV-TasP is a highly impactful and potent 
approach to control Pakistan’s HCV epidemic and achieve 
elimination by 2030.
IntrODuCtIOn
Viral hepatitis is the seventh leading cause of 
death globally.1 Half of viral hepatitis deaths are 
attributed to hepatitis C virus (HCV).1–3 Paki-
stan is one of the most affected countries by 
this virus where HCV antibody (Ab) prevalence 
is estimated at 4.3% in 2017,4 with genotype 3 
being most common in all provinces.5 Against 
this backdrop, HCV treatment has undergone 
a revolution since 2013. Introduction of direct-
acting antivirals (DAAs) furnished shorter and 
well-tolerated treatment regimens, with a success 
rate exceeding 90%.6 With the availability of 
DAAs, the WHO is calling for ambitious global 
targets for diagnosis, treatment and cure of 
viral hepatitis, signalling a major momentum 
towards HCV elimination by 2030.7 
The Ministry of Health in Pakistan has 
launched its first National Hepatitis Stra-
tegic Framework following the WHO global 
targets.8 9 Importantly, the Government of Paki-
stan has made a commitment to provide diag-
nosis, treatment and care to patients infected 
by HCV free of cost in all provinces, through 
four regional Hepatitis Prevention and Control 
programmes.8 HCV patients will have access 
to DAA generics (eg, generic sofosbuvir and 
daclatasvir) with a cost of <US$100 per treat-
ment course per person—one of the lowest 
costs globally.8–10
Following the recent proof-of-concept and 
approach of HCV treatment as prevention 
(TasP) in Egypt11 and our developed epide-
miological model for the HCV epidemic 
in Pakistan,4 we aimed to assess the impli-
cations of HCV-TasP in Pakistan. We did so 
through different scenarios for scaling up and 
sustaining the programme including an elimi-
nation scenario by 2030, where elimination is 
defined as an incidence rate of <1 per 100 000 
person-year.11
strengths and limitations of this study
 ► We used a nationally  representative survey and a 
comprehensive database of systematically gathered 
hepatitis C virus (HCV) antibody prevalence data to 
fit the scale and the trend of the HCV epidemic in 
Pakistan.
 ► We assessed the implications of HCV treatment 
as prevention in Pakistan using different plausible 
treatment scenarios from a conservative baseline 
scale-up scenario up to an ambitious elimination 
scenario.
 ► Future projections were generated by fitting the 
model to past and current data, but could be influ-
enced by factors difficult to predict at present.
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MAterIAls AnD MethODs
Mathematical model
Starting from our model for the Pakistan epidemic,4 we 
implemented an age-structured mathematical model as 
an adaptation and extension of earlier models and guide-
lines.4 11 12 Details of the model and parameterisation can be 
found in the supplementary material and in references.4 11
Briefly, the model is a population-level compartmental 
mathematical model that describes HCV transmission in 
the whole population. The model stratified the popu-
lation into categories according to level of HCV risk of 
exposure, status and stage of infection and age group. 
The model divided Pakistan’s population into seven age 
groups based on the available HCV Ab prevalence data, 
and accounted for heterogeneity in risk of exposure to 
the infection by incorporating five risk groups in the 
modelled population. Individuals from different risk 
and age groups mixed in the model according to mixing 
matrices that include both an assortative component and 
a proportionate component.4 11 13 14 The force of infec-
tion was defined in terms of the effective contact rates, 
HCV transmission probability per contact by HCV stage 
and mixing among the different age and risk groups.
Detailed descriptions of assumptions and model struc-
ture can be found in S1 Text and online supplementary 
table S1.
Data sources and model fitting
The model was parameterised using empirical data for 
HCV natural history and transmission (online supple-
mentary text S2 and table S2). Demographic data were 
derived from the database of the Population Division 
of the United Nations Department of Economic and 
Social Affairs,15 and Pakistan’s sixth Population and 
Housing Census-2017.16 Per our modelled epidemic in 
Pakistan,4 trends were estimated by fitting the model to 
a nationally representative and probability-based HCV 
Ab prevalence survey conducted in 2007–2008,17 and a 
comprehensive database of systematically gathered HCV 
Ab prevalence data.4 18 Detailed description of the model 
fitting to the data can be found in Ayoub et al.4
epidemiological and programme indicators
To inform public health response and following our 
approach for Egypt,11 we used epidemiological and 
programme indicators to assess the implications of Paki-
stan’s treatment programme. The definition of these 
measures can be found in online supplementary table S3. 
The year 2010 was chosen as a reference year for several 
comparisons of outcome measures as suggested by WHO 
as a reference year,7 19 to have comparisons over complete 
two decades (2010, 2020 and 2030), and for consistency 
with the approach for Egypt.11 Treatment cost per person 
was assumed at US$100, mainly covering the cost of the 
generic DAAs.9 20 Furthermore, we applied an annual 
discount rate of 3% on future expenditures and on future 
savings (the latter being defined as infections averted).
treatment programme scenarios
Informed by stakeholder discussions, programme data21 22 
and experiences with similar scope programmes,11 23 24 the 
treatment programme was assumed to start in 2018 with a 
phase where the programme is being scaled up and that 
ends in 2020, followed by a phase where the programme 
is sustained from 2021 up to 2030, the elimination year. 
We assumed that there are no restrictions on treatment 
eligibility for any chronically infected person, regard-
less of liver disease stage or age. Success rate of treat-
ment was assumed at 90%.25 We evaluated five HCV-TasP 
programme scenarios ranging from a conservative base-
line scale-up scenario up to an ambitious elimination 
scenario (summarised in figure 1).
Figure 1 Assessed scenarios of Pakistan’s HCV treatment programme. The key features of the five assessed treatment 
programme scenarios in both the scale-up and sustainability phases. 
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uncertainty analyses
To examine the range of uncertainty in the projected 
epidemic trajectories and treatment programme 
outcomes, we performed multivariable uncertainty 
analyses by implementing 1000 runs of the model. We 
assumed a 25% uncertainty around the parameters’ 
point estimates and applied Latin Hypercube sampling 
from a multidimensional distribution for the model’s 
structural parameters. Mean and associated 95% uncer-
tainty interval were reported for HCV-TasP effectiveness 
and HCV incidence rate reduction (see online supple-
mentary table S3 for definitions) by 2030 for each of 
the scenarios.
Patient and public involvement
Patients and/or public were not involved in this study.
results
Table 1 and figures 2-4 display the projected impact of the 
five programme scenarios. In absence of the programme, 
the epidemic was forecasted to decline slowly. While the 
prevalence of chronic infection and number of chron-
ically infected individuals (and in need of treatment) 
were estimated at 3.2% and 6 665 900 in 2018, they were 
projected to decline to 3.0% and 6 655 300 by 2020, 
and 2.6% and 6 372 100 by 2030, respectively (figure 2). 
Similarly, while HCV incidence rate per 100 000 person-
year and number of new infections were estimated at 94 
and 192 460 in 2018, they were projected to decline to 87 
and 183 860 by 2020, and 62 and 150 360 by 2030, respec-
tively (figure 3).
While total number of treatments administered by the 
end of the scale-up phase (in 2020) was 600 000 across the 
scenarios, by the end of the sustainability phase in 2030, 
it ranged between 0.6 million in the baseline scale-up 
scenario and 7.3 million in the elimination scenario. 
While incidence reduction was estimated at 27% by 2020 
(with respect to 2010 incidence), it ranged between 41% 
and 99% by 2030. While prevalence of chronic infection 
declined to 2.8% by 2020, it ranged between 2.4% and 
0.03% by 2030. While number of chronically infected 
individuals declined to 6 206 000 by 2020, it ranged 
between 5 868 600 and 8604 by 2030.
Annual reduction in incidence rate in the baseline 
scale-up scenario was around 6% per year up to 2020 and 
declined thereafter, but in the remaining scenarios, it 
ranged between 6% and 15% per year up to 2025 and 
then increased thereafter. While incidence rate reduction 
due to the programme was estimated at 6.1% by 2020, it 
ranged between 7.2% and 98.5% by 2030. While number 
of averted infections was estimated at 13 403 by 2020, it 
ranged between 126 221 and 750 547 by 2030.
Figure 2 Impact of the five treatment programme scenarios on HCV chronic infection in Pakistan. (A) Prevalence of chronic 
HCV infection in the total population of Pakistan in the baseline scenario of no-treatment-intervention compared with the five 
treatment programme scenarios. (B) Number of individuals with HCV chronic infection in the total population of Pakistan in the 
baseline scenario of no-treatment-intervention compared with the five treatment programme scenarios. HCV, hepatitis C virus. 
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Figure 3 Impact of the five treatment programme scenarios on HCV incidence in Pakistan. (A) HCV incidence rate in the total 
population of Pakistan in the baseline scenario of no-treatment-intervention compared with the five treatment programme 
scenarios. (B) Annual number of new HCV infections in the total population of Pakistan in the baseline scenario of no-treatment-
intervention compared with the five treatment programme scenarios. HCV, hepatitis C virus .
Figure 4 Incidence rate reduction in the scale-up phase and sustainability phase. (A) Incidence rate reduction in the total 
population of Pakistan strictly attributed to each of the five treatment programme scenarios. (B) Annual change in incidence rate 
in each of the five treatment programme scenarios.
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Table 1 and figure 5 show key programme indicators 
for all programme scenarios. Treatment coverage in 2020 
reached 6.2% across the scenarios, and by 2030, it ranged 
between 3.7% in the baseline scale-up scenario and 98.7% 
in the elimination scenario (figure 5A). Programme cost 
ranged between US$58.2 million and US$708.1 million by 
2030. HCV-TasP effectiveness was around 45 by 2020, 18 by 
2025 and 10 by 2030 across the various scenarios (table 1 
and figure 5B). Cost per infection averted declined from 
US$4336 by 2020 to around US$900 by 2030 across the 
scenarios (table 1).
The multivariable uncertainty analyses supported the 
validity of our results and findings (online supplementary 
figure S1).
DIsCussIOn
Pakistan is one of the most affected countries by HCV with 
about 10% of the global number of chronic infections, 
and 10% of the global HCV incidence.4 22 26 This study 
investigated and quantified the utility of HCV-TasP in this 
country and demonstrated that HCV-TasP is a strategic 
and indispensable approach to control the epidemic and 
to reach the WHO elimination target by 2030.
In context of availability of heavily discounted DAA 
generics in Pakistan, at a cost of <US$100 for a treatment 
course,9 20 27 there is a historic opportunity to control the 
HCV epidemic at a relatively low cost of <US$1 billion 
distributed over a decade and a half. This cost is minimal 
considering the future healthcare costs that are being 
averted, and other costs in terms of productivity, disability 
and premature mortality. With the time lag between 
infection and disease sequelae,28 lack of a meaningful and 
immediate scale-up of HCV-TasP will be translated into 
a growing disease burden of liver cirrhosis and cancer 
that Pakistan cannot afford. The strikingly persistent 
incidence4 adds up to an immense opportunity cost with 
failure to control the epidemic.
In all scenarios, HCV-TasP achieved substantial if not 
huge impact on incidence and chronic infection prev-
alence. By 2030, prevalence of chronic infection can 
reach 2.4%–0.03%, incidence reduction ranged between 
41%–99% and incidence rate reduction due to the 
programme ranged between 7%–98%. The impact of 
the programme was also prompt to materialise with an 
annual incidence rate reduction of around 6% in the 
initial years. In the most ambitious elimination scenario, 
a total of 7.3 million individuals would have been treated 
and around 750 000 infections would have been averted, 
by 2030. For every nine DAA treatments, one infection 
would be averted by 2030, at a cost of about US$900. 
These key programme indicators illustrate how HCV-TasP 
is a cost-effective and potent intervention, and very likely 
a cost saving one against disease sequelae costs.
Pakistan has launched its first National Hepatitis Stra-
tegic Framework where free diagnosis, treatment,and 
care are being provided to infected people in different 
provinces through four Hepatitis Prevention and Control 
programmes.8 Pakistan has one of the least expensive 
Figure 5 Key programme indicators for the five treatment programme scenarios. (A) Treatment coverage defined as proportion 
of all those living with chronic HCV infection that have been treated with direct-acting antivirals. (B) Effectiveness of HCV 
treatment as prevention (HCV-TasP) defined as number of treatments required to avert one new HCV infection. HCV, hepatitis C 
virus; HCV-TasP, hepatitis c virus treatment as prevention.
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DAAs worldwide with the introduction of locally produced 
generics.9 27 Despite the affordability of DAAs,20 scale-up 
has been very modest with only 311 000 treated infections 
since DAA introduction in 2013.22 Our results indicate 
that the WHO global target of 80% incidence reduction 
by 2030 cannot be attained unless the number of treat-
ments per year reaches 490 000, and is kept at this level 
for a decade.
A recent modelling work also assessed the impact of 
HCV-TasP in Pakistan.29 The authors’ conclusions agreed 
with our conclusions that HCV-TasP is an effective and 
compelling intervention against HCV transmission. 
However, some of the results differed. They projected an 
increase in incidence and chronic infection prevalence 
in absence of treatment, but our analyses projected a 
slow decline. This difference arose from differences in 
the model input data. They used data of the national 
(2007–2008) survey,17 surveys among people who inject 
drug (PWID) and blood donor testing. Meanwhile, we 
used data of the national (2007–2008) survey and an 
extensive database of HCV Ab prevalence data generated 
through a systematic review.4 18 Their analyses considered 
also different treatment programme scenarios than ours. 
With the differences in epidemic projections, they esti-
mated substantially higher number of treatments to reach 
the WHO global target by 2030 than we did.
The relevance and feasibility of scaling up Pakistan’s 
programme can be seen in Egypt’s successful experience 
of scaling up the treatment programme.11 30 31 With the 
rapidly declining incidence and two million less prevalent 
chronic infections in Egypt,11 Pakistan’s programme can 
be even more impactful. By reaching elimination by 2030, 
the number of averted infections will be more than 50% 
higher than that in Egypt and more cost effective—10 
treatments are needed to avert one infection in Pakistan 
compared with 12 in Egypt.
Despite the opportunity for scaling up HCV-TasP, the 
programme may soon encounter a major hurdle: iden-
tifying chronically infected individuals. The programme 
will not be able to yield its potential without active case 
finding. Our understanding of HCV epidemiology in 
Pakistan remains insufficient to develop cost-effective 
screening strategies,4 18 unlike Egypt where the epidemic 
is thoroughly investigated.11 32–40 While an understanding 
of epidemic drivers is being developed,18 41 screening 
can initially target >40 birth cohorts, who are more 
affected,4 17 and provinces with higher prevalence.17 With 
evidence for a major role for healthcare exposures18 42 
and injecting drug use,18 43 44 targeting screening to these 
settings could be effective. Screening can also be scaled 
up using awareness campaigns and accessible mobile and 
fixed testing units, and should be targeting geographic 
localities with higher HCV prevalence.34
A recent study provided a conceptual map for a testing 
programme with focus on Pakistan and Egypt.45 The study 
showed that testing strategies can be much more efficient 
through population prioritisation by risk of exposure. 
For example, testing efficiency was highest by targeting, 
respectively, populations with liver conditions, PWID, 
populations with high-risk healthcare exposures and 
special clinical populations, where only 2–4 tests would 
be needed to identify a chronic infection, followed by 
populations at intermediate risk, and eventually general 
populations.
Current evidence suggests that HCV transmission in 
Pakistan is mostly driven by healthcare-related exposures, 
such as poor sterilisation of medical equipment, intrave-
nous infusions and therapeutic injections.18 46–50 Although 
Pakistan has made strides to improve blood screening, 
safe injection and other infection control measures, 
and has been increasing HCV treatment coverage,10 51–54 
commitment to prevention in the different segments of 
the healthcare system is warranted for this country to 
reduce further HCV incidence and to accomplish the 
HCV elimination target by 2030.
As for limitations of the present analyses, we did 
not include previous treatments (prior to 2018), but 
treatment coverage has been limited up to today.22 
We assumed any chronically infected individual can 
be treated, but treatment may not be indicated for all. 
The cost per infection averted included only the cost 
of the drug and its direct implementation, but it did 
not include the cost of screening/testing to identify the 
chronically infected individuals. Future work needs to 
explore the cost effectiveness of combined HCV testing 
and treatment programmes. Most biological parameters 
used in the model were found in the literature based on 
studies including PWID, which may affect their general-
isability. Future incidence can be uncertain as it depends 
on unpredictable factors, such as scale-up of other inter-
ventions. We used a complex mathematical model to 
describe HCV transmission in the population, but predic-
tions may be contingent on type of model and its input 
data. To account (partially) for limitations, we performed 
multivariable uncertainty analyses, and these affirmed 
our results (online supplementary figure S1).
In conclusion, we assessed the impact of HCV-TasP 
in Pakistan through different programme scenarios. 
Projected programme outcomes demonstrated HCV-TasP 
as a strategic and indispensable approach to control the 
epidemic and to achieve elimination by 2030. Pakistan 
has a golden opportunity to avert 750 000 new infections, 
and to eliminate much of HCV chronic infections by 
expanding its treatment programme.
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